Rallybio (RLYB) to Release Quarterly Earnings on Thursday

Rallybio (NASDAQ:RLYB) is expected to release its results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.28) per share and revenue of $0.2210 million for the quarter.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%. The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million.

Rallybio Stock Performance

Shares of NASDAQ:RLYB opened at $15.96 on Thursday. Rallybio has a one year low of $3.20 and a one year high of $17.57. The stock has a market capitalization of $84.59 million, a price-to-earnings ratio of -3.68 and a beta of -0.90. The company has a 50-day simple moving average of $15.90 and a 200-day simple moving average of $10.92.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rallybio has an average rating of “Sell”.

Insider Activity at Rallybio

In other Rallybio news, major shareholder Adar1 Capital Management, Llc purchased 10,200 shares of Rallybio stock in a transaction dated Tuesday, May 19th. The stock was acquired at an average cost of $13.98 per share, with a total value of $142,596.00. Following the acquisition, the insider directly owned 926,352 shares of the company’s stock, valued at $12,950,400.96. This represents a 1.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders purchased 302,473 shares of company stock valued at $4,229,715. 10.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. XTX Topco Ltd boosted its position in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after purchasing an additional 38,205 shares in the last quarter. Susquehanna International Group LLP grew its stake in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares during the period. Geode Capital Management LLC increased its holdings in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares during the period. Hedge funds and other institutional investors own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.